Feasibility and Value of Quantitative Dynamic Contrast Enhancement MR imaging in Evaluation of Orbital Masses in Adults
Liyuan Song1, Lizhi Xie2, and Junfang Xian1

1Department of Radiology,Beijing Tongren Hospital,Capital Medical Universityy, Beijing, China, People's Republic of, 2GE Healthcare, MR Research China, Beijing, Beijing, China, People's Republic of

Synopsis

This work assessed the feasibility of quantitative parameters derived from dynamic contrast enhanced MR imaging (DCE-MRI) and evaluate the value of quantitative dynamic contrast enhanced MR imaging in the diagnosis and differential diagnosis of orbital masses in adults. From the result we can see that it is feasible that quantitative parameters of orbital masses can be derived from DCE-MRI. ROI onf the earliest and most enhanced area was optimal for distinguishing benign masses from malignant masses in orbit.

Purpose

To assess the feasibility of quantitative parameters derived from dynamic contrast enhanced MR imaging (DCE-MRI) and evaluate the value of quantitative dynamic contrast enhanced MR imaging in the diagnosis and differential diagnosis of orbital masses in adults.

Methods

One hundred and forty two patients with orbital masses confirmed by pathology were enrolled in the study consisting of 89 benign masses and 53 malignant masses in orbit [1,2]. Three methods of selecting regions of interest (ROI) [3,4] were compared to obtain quantitative parameters: (a) covering the whole lesion on the largest slice, (b) a round or ovoid region of 8mm2 covering the earliest and most enhanced area, and (c) covering the lesion excluding the hemorrhage and necrosis on the largest slice (Figure.1). Parametric maps were obtained for quantitative parameters including KtransVe and Kep (Figure.2). Quantitative parameters that distinguishing benign from malignant masses were analyzed by using independent rank sum test, independent T-test, receiver operating characteristic curves (ROC) and Z test. P value of less than 0.05 was considered to represent a significant difference.

Results

There were significant differences between orbital benign and malignant masses in Ktrans and Kep (p<0.01)(Table.1). However, Ve showed no difference between orbital benign and malignant masses(p>0.05). ROI on the earliest and most enhanced area was best for distinguishing benign from malignant masses in orbit (p<0.05) (Table.2). The corresponding Ktrans distinguished malignant masses from benign masses with sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 79.2%, 64.0%, 56.7%, 83.8%, 69.7% respectively. The corresponding Kep distinguished malignant masses from benign masses with sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 88.7%, 59.6%, 56.7%, 89.8%, 70.4% respectively.

Conclusions

It is feasible that quantitative parameters of orbital masses can be derived from DCE-MRI. ROI on the earliest and most enhanced area was optimal for distinguishing benign masses from malignant masses in orbit.

Acknowledgements

No acknowledgement found.

References

[1] Xian J, et al. European Radiology, 2010, 20(7): 1692-1702.
[2] Khalek AA, et al. Neuroradiology, 2011, 53(7): 517-522.
[3] Yankeelov TE, et al. Magnetic Resonance Imaging, 2005, 23(4): 519-529.
[4] Craciunescu OI, et al. International Journal of Radiation Oncology, Biology, Physics, 2012, 82(3): 345-350.

Figures

Figure.1 Three methods of selecting regions of interest (ROI). (a) covering the whole lesion on the largest slice; (b) a round or ovoid region of 8mm2 covering the earliest and most enhanced area; (c) covering the lesion excluding the hemorrhage and necrosis on the largest slice.

Figure.2 The orbital lymphoma . Parametric maps for quantitative parameters including (a) Ktrans,(b) Ve and (c) Kep.

Table.1 Comparision of quantitative parameters between orbital benign and malignant masses.

Table.2 Positive predictive values, negative predictive values, sensitivity, specificity and accuracy of MR imaging features in evaluating malignant versus benign diseases in patients with orbital soft tissue masses.



Proc. Intl. Soc. Mag. Reson. Med. 24 (2016)
1475